Stringer F., Ploeger B.A., Jongh J.d., Scott G., Urquhart R., Karim A. and Danhof M., Evaluation of the Impact of UGT Polymorphism on the Pharmacokinetics and Pharmacodynamics of the Novel PPAR Agonist Sipoglitazar, J Clin Pharmacol., 53(3): 256-263, 2013. [Link to publication]
Stringer F., Dejongh J., Scott G. and Danhof M., A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar, J Clin Pharmacol, 11(10): 227, 2013. [Link to publication]
Stringer F., Ploeger B., Jongh J.d., Scott G., Urquart R., Karim A. and Danhof M., Genotyped versus phenotyped dosing to account for UGT polymorphism of the novel PPAR agonist sipoglitazar PAGE.(2009). [Link to publication]
Winter W.d., Jongh J.d, Post T., Ploeger B., Urquhart R., Moules I., Eckland D. and Danhof M., A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus, J Pharmacokinet Pharmacodyn., 33(3): 313-343., 2006. [Link to publication]
Post T.M., Winter W.d., Jongh J.d., Moules I., Urquhart R., Eckland D. and Danhof M., Treatment Efficacy of Combination-Therapy based on a Mechanistic Characterisation of Disease Processes in Type 2 Diabetes Mellitus over a two-year period. PAGE.(2005). [Link to publication]
Freijer J., Greef I.d., Post T. and Ploeger B., Robust fitting of pharmacokinetic models to Phase II/III clinical trial data. PAGE.(2005). [Link to publication]
Winter W.d., Jongh J.d., Urquhart R., Moules I., Eckland D. and Danhof M., Mechanistic Disease Progression Analysis Indicates that Pioglitazone Improves ß-cell Function in Treatment-naïve Type 2 Diabetics. ADA.(2005).
Post T., Winter W.d., Jongh J.d., Urquhart R., Moules I., Eckland D. and Danhof M., Treatment efficacy of Pioglitazone in Combination Therapy on Disease Progression in Type 2 Diabetes Mellitus over a two-year period. ADA.(2005).
Winter W.d., Cascading Disease Progression Analysis in Type 2 Diabetes: Integrating multiple biomarkers into single mechanism-based model. PharmSciFair.(2005).
Post T.M., Winter W.d., Jongh J.d., Moules I., Urquhart R., Eckland D. and Danhof M., Treatment Efficacy of Combination-Therapy based on a Mechanistic Characterisation of Disease Processes in Type 2 Diabetes Mellitus over a two-year period. Figon.(2005).
- « Previous
- 1
- 2
- 3
- Next »